Guerbet — Board/Management Information 2014

Nov 5, 2014

P R E S S R E L E AS E

Céline Lamort co-opted to Guerbet Board of Directors

following resignation of Olivier Guerbet

Villepinte, 5 November 2014

The Board of Directors of Guerbet, an international pharmaceutical group specialized in medical imaging, has co-opted Céline Lamort to the Board. The decision will be submitted to ratification at Guerbet's next Annual General Meeting of Shareholders on 29 May 2015.

This appointment follows the resignation of Olivier Guerbet from the Board of Directors. Olivier Guerbet, a member of the Guerbet Board since May 2001, wishes to devote himself fully to his work with the René Briand Group – France's no.1 firm supplying seedlings to market garden professionals – of which he has been Chairman and CEO since 2012.

Céline Lamort, 32 years old, a graduate of the Chimie ParisTech (ENSCP), Paris, has ten years' professional experience in the chemical industry where she has occupied various functions within production, maintenance and supply chain in the Netherlands and United States. Since 2013 she has been Operations Manager with Royal DSM N.V., with which she has been all her professional life.

She also holds a board member certificate from the French Institute of Directors (IFA).

Céline Lamort is a member of the Guerbet family shareholders' pact.

Guerbet's Board of Directors is composed of nine members:

• Marie-Claire Janailhac-Fritsch, Chairman
• Marion Barbier
• Jean-Jacques Bertrand
• Mark Fouquet
• Didier Izabel
• Céline Lamort
• Yves L'Epine
• Christian Louvet
• Claire Massiot-Jouault

About Guerbet

A pioneer in the field of contrast agents with more than 80 years of experience, Guerbet is the only pharmaceutical group fully dedicated to medical imaging worldwide. As such it has a complete offering of contrast agents for X-ray and MRI and for interventional radiology, along with a range of injectors and related medical equipment to provide improved diagnosis and treatment of patients. To promote the discovery of new products and assure future growth, Guerbet devotes significant resources to research and development every year (approximately 10% of sales). Guerbet (GBT) is listed on the NYSE Euronext Paris market (Eurolist Segment B – Mid Caps) and had sales of €390 million in 2013 with a total workforce of 1,485 employees, with over 1,000 in France.

For additional information about Guerbet please go to www.guerbet.com.

Press contacts:

Anne-Laure Delasalle, Communications Director

Tel.: + 33 (0)1 45 91 50 03 anne-laure.delasalle@guerbet-group.com